114 related articles for article (PubMed ID: 10430261)
1. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium.
Sweeney CJ; Williams SD; Finch DE; Bihrle R; Foster RS; Collins M; Fox S; Roth BJ
Cancer; 1999 Aug; 86(3):514-8. PubMed ID: 10430261
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
[TBL] [Abstract][Full Text] [Related]
5. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
Galsky MD; Iasonos A; Mironov S; Scattergood J; Donat SM; Bochner BH; Herr HW; Russo P; Boyle MG; Bajorin DF
Urology; 2007 Feb; 69(2):255-9. PubMed ID: 17320659
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
Krege S; Rembrink V; Börgermann C; Otto T; Rübben H
J Urol; 2001 Jan; 165(1):67-71. PubMed ID: 11125366
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932
[TBL] [Abstract][Full Text] [Related]
10. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.
Small EJ; Lew D; Redman BG; Petrylak DP; Hammond N; Gross HM; Eastham JA; Crawford ED
J Clin Oncol; 2000 Jul; 18(13):2537-44. PubMed ID: 10893284
[TBL] [Abstract][Full Text] [Related]
11. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
13. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
Friedland DM; Dakhil S; Hollen C; Gregurich MA; Asmar L
Cancer Invest; 2004; 22(3):374-82. PubMed ID: 15493358
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
Johannsen M; Sachs M; Roigas J; Hinke A; Staack A; Loening SA; Schnorr D; Wille AH
Eur Urol; 2005 Aug; 48(2):246-51. PubMed ID: 15963636
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
Pagliaro LC; Millikan RE; Tu SM; Williams D; Daliani D; Papandreou CN; Logothetis CJ
J Clin Oncol; 2002 Jul; 20(13):2965-70. PubMed ID: 12089226
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study.
Dreicer R; Manola J; Roth BJ; Cohen MB; Hatfield AK; Wilding G
J Clin Oncol; 2000 Mar; 18(5):1058-61. PubMed ID: 10694557
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.
Redman BG; Smith DC; Flaherty L; Du W; Hussain M
J Clin Oncol; 1998 May; 16(5):1844-8. PubMed ID: 9586899
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Latreille J; Crump M; Stewart D; Tomiak E; Eisenhauer E; Fisher B
Ann Oncol; 1996 Mar; 7(3):311-3. PubMed ID: 8740797
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
